MedTrace Logo

Dasatinib in Resectable Malignant Pleural Mesothelioma

NCT00652574 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2022-10-31

No results posted yet for this study

Summary

The goal of this clinical research study is to learn how dasatinib affects biomarker levels in patients with malignant pleural mesothelioma that may be able to be removed by surgery. The safety and effectiveness of this drug will also be studied.

This research study is financially supported by the United States Department of Defense.

Conditions

  • Malignant Pleural Mesothelioma

Interventions

DRUG

Dasatinib

70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • United States Department of Defense

    collaborator FED

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Anne S. Tsao, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-12
Primary Completion
2022-10-07
Completion
2022-10-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652574 on ClinicalTrials.gov